Blueprint Medicines (NASDAQ:BPMC) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Monday.
Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research note on Friday, February 23rd. ValuEngine raised shares of Blueprint Medicines from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Cowen reissued a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $84.20.
Shares of NASDAQ BPMC opened at $98.98 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 15.98 and a quick ratio of 15.98. The firm has a market capitalization of $4,325.83, a PE ratio of -25.25 and a beta of 0.96. Blueprint Medicines has a 1 year low of $34.38 and a 1 year high of $109.00.
Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.07) by ($0.16). The firm had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $5.28 million. Blueprint Medicines had a negative return on equity of 38.79% and a negative net margin of 691.30%. The business’s revenue for the quarter was down 78.8% on a year-over-year basis. During the same period last year, the company earned ($0.75) earnings per share. research analysts predict that Blueprint Medicines will post -4.85 earnings per share for the current fiscal year.
In related news, Director Nicholas Lydon sold 25,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $87.89, for a total transaction of $2,197,250.00. Following the completion of the transaction, the director now owns 193,131 shares in the company, valued at $16,974,283.59. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Lynch sold 17,500 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $74.84, for a total transaction of $1,309,700.00. Following the transaction, the director now owns 202,812 shares of the company’s stock, valued at approximately $15,178,450.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,567 shares of company stock valued at $7,651,106. 3.40% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Xact Kapitalforvaltning AB bought a new position in Blueprint Medicines during the fourth quarter valued at $290,000. Alkeon Capital Management LLC bought a new position in Blueprint Medicines during the fourth quarter valued at $754,000. Dumont & Blake Investment Advisors LLC bought a new position in Blueprint Medicines during the fourth quarter valued at $302,000. MetLife Investment Advisors LLC bought a new position in Blueprint Medicines during the fourth quarter valued at $1,461,000. Finally, Kazazian Asset Management LLC lifted its position in Blueprint Medicines by 15.8% during the fourth quarter. Kazazian Asset Management LLC now owns 28,646 shares of the biotechnology company’s stock valued at $2,160,000 after purchasing an additional 3,911 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.
WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/16/blueprint-medicines-bpmc-raised-to-buy-at-bidaskclub.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.